Weekly ascorbic acid infusion in castration-resistant prostate cancer patients:A single-arm phase II trial by Nielsen, Torben K. et al.
Syddansk Universitet
Weekly ascorbic acid infusion in castration-resistant prostate cancer patients
A single-arm phase II trial
Nielsen, Torben K.; Højgaard, Martin; Andersen, Jon T.; Jørgensen, Niklas Rye; Zerahn, Bo;
Kristensen, Bent; Henriksen, Trine Maxel; Lykkesfeldt, Jens; Mikines, Kári J.; Poulsen, Henrik
E.
Published in:
Translational Andrology and Urology
DOI:
10.21037/tau.2017.04.42
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Citation for pulished version (APA):
Nielsen, T. K., Højgaard, M., Andersen, J. T., Jørgensen, N. R., Zerahn, B., Kristensen, B., ... Poulsen, H. E.
(2017). Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: A single-arm phase II trial.
Translational Andrology and Urology, 6(3), 517-528. DOI: 10.21037/tau.2017.04.42
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Sep. 2018
Transl Androl Urol 2017;6(3):517-528tau.amegroups.com© Translational Andrology and Urology. All rights reserved.
Original Article
Weekly ascorbic acid infusion in castration-resistant prostate 
cancer patients: a single-arm phase II trial
Torben K. Nielsen1,2, Martin Højgaard1, Jon T. Andersen3,4, Niklas Rye Jørgensen5,6, Bo Zerahn7, Bent 
Kristensen7, Trine Henriksen3,4, Jens Lykkesfeldt2, Kári J. Mikines1,2, Henrik E. Poulsen2,3,4
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HE Poulsen; (IV) Collection and assembly of data: TK Nielsen, M Højgaard, KJ Mikines; (V) Data analysis and interpretation: TK Nielsen, NR 
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Background: Ascorbic acid (AA) has in vivo cytotoxic properties at concentrations that can only be 
achieved through intravenous (IV) administration in humans. Treatment with intravenous AA is widely 
and increasingly used in complementary medicine despite a lack of clinical evidence for the efficacy of this 
treatment.
Methods: This non-comparative, single-center, phase II trial included patients with chemotherapy-naïve, 
metastatic castration-resistant prostate cancer (mCRPC) from an outpatient clinic to evaluate the efficacy and 
safety of IV AA therapy. Patients received weekly infusions of AA (week 1, 5 g; week 2, 30 g; and weeks 3–12, 
60 g) followed by efficacy evaluation at 12 weeks. The primary endpoint for efficacy was a 50% reduction in 
the prostate-specific antigen (PSA) level. The secondary endpoints included changes in health-related quality 
of life (HRQoL), biomarkers of bone metabolism, inflammation and bone scans. Clinicaltrials.gov identifier: 
NCT01080352.
Results: Twenty-three patients were enrolled in this study, and 20 completed the efficacy evaluation at 
12 weeks. The mean baseline PSA level was 43 µg/L. No patient achieved a 50% PSA reduction; instead, 
a median increase in PSA of 17 µg/L was recorded at week 12. Among the secondary endpoints, no signs 
of disease remission were observed. In total, 53 adverse events (AEs) were recorded. Eleven were graded as 
“serious”. Three AEs were directly related to AA, and all of which were related to fluid load.
Conclusions: Infusion with 60 g of AA did not result in disease remission. This study does not support the 
use of intravenous AA outside clinical trials. 
Keywords: Prostatic neoplasms; cancer; ascorbic acid (AA); complementary medicine; translational medical 
research 
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Introduction
The use of complementary and alternative medicine (CAM) 
is becoming increasingly popular for the treatment of 
patients diagnosed with cancer. Thirty percent of prostate 
cancer (PC) patients are treated with at least one CAM 
method (1). Metastatic castration-resistant prostate cancer 
(mCRPC) is the end stage in a sequence of PC disease 
landmarks. The initial phase of mCRPC is asymptomatic, 
with progression only being detectable by biomarkers and 
imaging techniques. Following the asymptomatic window, 
a period of increased mortality is observed, with a median 
survival of 2–3 years. 
Treatment with intravenous (IV) ascorbic acid (AA) 
is widely used in CAM clinics (2), but quality evidence 
regarding the efficacy and safety of this treatment is lacking. 
Indeed, two randomized controlled trials (3,4) of oral AA 
for the treatment of advanced cancers were not able to 
reproduce the improved overall survival (OS) that was 
observed in a large case series reported in the 1970s (5,6).
AA shows in vitro cytostatic and cytotoxic properties in 
tumor cell lines, including the NCI60 screening panel, and to 
have some in vivo cytostatic and cytotoxic properties (7,8). The 
mechanisms underlying these properties of AA have not been 
fully elucidated, and it remains unclear whether the effect of 
AA on tumor level, if any, is able to stabilize the disease or cause 
remission. The cytotoxic concentrations of AA are more than 
100-fold higher than those obtainable by oral administration 
and can only be achieved by IV administration (9), 
which was not used in the randomized controlled trials (3,4). 
The average IV AA dose used in CAM for various indications, 
including cancer, is 28 g every 4 days (2).
The present study investigated the efficacy and safety 
of weekly high-dose IV AA in mCRPC patients using 
standardized clinical trial principles (10,11).
Methods
Study design
The study was designed as a non-comparative, single-center, 
phase II trial. Patients were recruited from the outpatient 
urology clinic at Copenhagen University Hospital Herlev. 
The study was initially designed with 20-g infusions, but the 
dose was increased after the enrollment of eight participants 
(unpublished data), as the predefined plasma concentration 
range was not obtained with 20-g infusions. All patients 
continued their normally scheduled visits to ensure the best 
standard of care. If patients were referred to chemotherapy, 
their participation in the present trial was discontinued.
Patient eligibility
The eligibility criteria included adenocarcinoma of the 
prostate with at least one metastatic lesion visible by 
bone or CT scan; ongoing androgen-deprivation therapy 
with castration-level testosterone (<1.7 nmol/L); disease 
progression [indicated by prostate-specific antigen (PSA) 
level or imaging findings] as defined by the Prostate 
Cancer Clinical Trials Working Group (PCWG-2) (10), no 
prior chemotherapy; and Eastern Cooperative Oncology 
Group (ECOG) performance of 0–2. The key exclusion 
criteria were surgical removal or radiation of the prostate; 
significant renal impairment; significant cardiac disease; 
history of oxalate renal stones; hemochromatosis; and 
glucose-6-phosphate dehydrogenase deficiency. 
All patients signed informed consent forms. The trial 
was approved by the Regional Ethics Committee (H-C-
2009-018), the Danish Health and Medicines Authority 
(2612-3978), and the Danish Data Protection Agency 
(2007-58-0015/750.19-15). It was registered (Eudra-CT 
2008-008692-33/NCT01080352) and followed the current 
Guidelines for Good Clinical Practice and the Declaration 
of Helsinki. 
Intervention
Patients received one weekly infusion of AA, as previously 
described (12). In brief, the initial dose was 5 g, followed by 
30 g in week 2 and a final dose of 60 g in week 3. The infusion 
rate was 1 g/min. The trial target dose of 60 g was continued 
once per week until the initial efficacy evaluation at 12 weeks. 
Patients were also given a daily oral dose of 500 mg AA from 
the first infusion, and it was continued for 26 weeks to avoid a 
hypothetical rebound deficiency following infusion (13). 
Statistical considerations
Data were analyzed using R v.3.0.3. Data are presented 
as medians along with a Q1–Q3 interquartile range. Data 
collected at baseline and at week 12 were compared using 
a predefined paired non-parametric statistical test due to 
the study design and the small sample size. A P value <0.05 
was considered statistically significant. The number of 
participants needed to achieve sufficient statistical power 
was calculated based on the primary efficacy marker using a 
slightly modified Ahern’s study design (14). The minimum 
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response was determined based on TAX327-controls (15). 
p0 was estimated as 5%, p1 =30%, α =0.05 and power =80%. 
Further investigations were warranted if ≥3 of the 20 
patients met the primary endpoint for efficacy. 
Trial evaluation (efficacy and safety)
Drug
Plasma AA concentrations were measured at the end of the 
infusion and 30 minutes after the end of the infusion on 
weeks 1–6, 9, and 12. The predefined goal for plasma AA 
concentration was >5–10 mM. The analytical procedures 
have been described previously (16). 
Efficacy 
The primary endpoint for efficacy was binary and was 
defined as ≥50% PSA reduction from baseline to 12 weeks. 
If achieved, an optional 8-week extension of the AA 
treatment was offered. The following additional biomarkers 
from the Halabi (17) and Smaletz (18) prognostic model 
were collected as markers of potential efficacy: hemoglobin 
(Hgb), lactate dehydrogenase (LDH), alkaline phosphatase 
(ALP), and albumin levels. All venous blood samples were 
subjected to standard accredited analysis at the Department 
of Clinical Biochemistry, Herlev University Hospital 
immediately after sampling. Biomarkers of bone metabolism 
were included to provide information on turnover rate, 
including two markers of bone formation and one marker of 
bone resorption: bone-specific alkaline phosphatase (bALP; 
an isoform of ALP), pro-collagen type I N-terminal (PINP), 
and urinary type I collagen cross-linked N telopeptides 
(uNTx). bALP was measured in venous serum blood 
samples, and uNTx was measured in spot urine samples 
(second morning void), normalized to urine creatinine, and 
analyzed at the Department of Clinical Chemistry, Aarhus 
University Hospital. PINP was measured in venous serum 
blood samples at the Department of Clinical Chemistry, 
Copenhagen University Hospital Glostrup. 
Metastatic burden in bone was evaluated by 99 m-Tc 
bisphosphonate bone scans at weeks 0, 12, 26, and 52. 
Bone scans were performed as routine investigations at the 
institutional Department of Clinical Physiology and were 
analyzed using a computerized detection system (EXINI 
bone software) to minimize interpretation bias (19). A link 
between inflammation and cancer has been suggested by 
epidemiological and experimental data (20,21). To quantify 
the inflammatory response and the level of oxidative stress, 
biomarkers of both parameters were measured, namely 
C-reactive protein (CRP), YKL-40, 8-oxo-7, 8-dihydro-
2’-deoxyguanosine (8-oxodG), and 8-oxo-guanosine 
(8-oxoGuo). The CRP level was analyzed at the Department 
of Clinical Biochemistry, Herlev University Hospital, 
immediately after sampling. The analytic kit was not 
highly sensitive; hence, concentrations below 3 mg/L were 
reported as “<3”. The plasma YKL-40 level was analyzed 
at the Department of Medicine, Copenhagen University 
Hospital Herlev. Markers of oxidative stress-induced DNA 
(8-oxodG) and RNA (8-oxoGuo) damage were measured 
in urine samples collected over a 24-h period, which ended 
on the day of baseline sampling and on the day of the last 
infusion; this analysis was performed at the Laboratory of 
Clinical Pharmacology, Copenhagen University Hospital 
Rigshospitalet. Performance status was recorded at every visit 
using the ECOG Performance Status Scale (22). Changes 
in health-related quality of life (HRQoL) were assessed by 
the European Organization for Research and Treatment 
of Cancer (EORTC) self-administered questionnaires 
QLQ-C30 (v3.0) (23) and QLQ-PR25 (24). Scores were 
transformed to a 0–100 scale according to the manuals of the 
questionnaires with the R package “QoLR v1.0”. 
Safety
Patients remained under observation by the study personnel 
during the infusion and for 30 min afterwards. Blood was 
screened for hemolysis 30 min after the infusion. Every 
3 weeks, a “safety blood-chemistry profile” was drawn to 
examine liver toxicity, kidney function, and electrolyte and 
hemoglobin levels. All adverse events (AE) were scored 
using the Common Terminology Criteria for Adverse 
Events v4.03 (CTCAE) (25). Deviations from the reference 
values present at baseline were only classified as AEs in 
cases of progression by one CTCAE grade.
Long-term follow-up
Follow-up visits were planned at 20, 26 and 52 weeks 
after trial initiation to monitor the long-term effects of 
the treatment on potential responders. All of the efficacy 
markers were evaluated at each follow-up visit. Follow-
up was discontinued if the patient was enrolled in another 
clinical trial or if chemotherapy was initiated.
Results
Patient characteristics
Twenty-three patients were enrolled in this study between 
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October 2011 and November 2013. All patients were 
male Caucasians. Detailed baseline characteristics of all 
the enrolled patients are shown in Tables 1 and 2. Prior 
to enrollment, patients received a least one additional 
hormone manipulation other than androgen deprivation 
therapy. Three patients discontinued treatment before the 
initial efficacy evaluation. Details are provided in Figure 1.
Drug evaluation
With the infusion of 60 g of AA (0.74 g/kg, Q1–Q3: 
0.66–0.81), all patients reached an AA plasma concentration 
within the predefined range. At infusion, the mean 
termination plasma AA concentration was 19.3 mM, and 
it was 15.1 mM after an additional 30 min. The detailed 
pharmacokinetic data of 10 participants have been 
published previously (12). The median baseline AA level 
was 54 µM (Q1–Q3: 45.6–73.5). At week 26, when oral AA 
supplementation was terminated, the median plasma AA 
was 88.4 µM (range 45.0–146.6 µM); hence, the patients 
Table 1 Baseline characteristics of all patients enrolled 
Variable (n=23) Median Q1 Q3
Age, years 73.8 69.2 79.6
Weight, kg 81.0 74.5 91.5
BMI, kg/m2 26.2 24.3 28.4
Creatinine, µmol/L 80 74 88
eGFR, mL/min 84 74 90
PSA, µg/L 43 21 72
Time from diagnosis to trial, months 50.7 28.6 90.5
BMI, body mass index; eGFR, estimated glomerular filtration 
rate calculated with the MDRD formula; PSA, prostate-specific 
antigen.
Table 2 Baseline characteristics of all patients enrolled 
Variable (n=23) No. %
Gleason score at diagnosis
7 3 13
8 9 39
9 10 43
10 1 4
ECOG PS
0 18 78
1 5 22
Bone metastasis 22 96
Visceral metastasis without bone metastasis 1 4
ECOG PS, Eastern Cooperative Oncology Group Performance 
Status.
Patients evaluated for enrollment, 
n=59
Met inclusion criteria
n=23
Completed to initial efficacy 
evaluation at 12 weeks, n=20
Follow-up until 52 weeks, n=6
Did not wish to participate, n=18
Not metastatic disease, n=9
Referred to/wished chemotherapy, n=3
Not castration resistant, n=2
Non-castrate testosterone level, n=1
Participated in other clinical trial, n=1
Creatinine >200, n=1
Low G6DP activity, n=1
Discontinued before week 12:
due to disease progression, n=2
due to percieved side effects, n=1
Discontinued follow-up before week 20, n=5
Discontinued follow-up before week 26, n=1
Discontinued follow-up before week 52, n=8
Figure 1 Trial flowchart of enrollment and discontinuation.
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were non-deficient (8).
Efficacy evaluation
Data from all of the patients who completed the study 
protocol until the initial efficacy evaluation at 12 weeks are 
summarized in Tables 3-6. No patients achieved the primary 
endpoint for efficacy, i.e., a PSA reduction of 50%. Baseline-
normalized percentage changes are presented in Figure 2. 
Fifteen patients (75%) displayed a nominal PSA increase, 
although three of these patients did not meet the PCWG-2 
criteria for progression (>25% increase). Nine of 20 patients 
at week 6 and 10 of 20 patients at week 9 experienced PSA 
progression. Overall, PSA increased by 17 µg/L (Q1–Q3: 
Table 3 Biomarkers for efficacy in all patients evaluated for the extension arm at week 12
Biomarker
Week 0 (n=20) Week 12 (n=20) Week 20 (n=15) Week 26 (n=14) Week 52 (n=6)
Median Q1 Q3 Median Q1 Q3 Median Q1 Q3 Median Q1 Q3 Median Q1 Q3
PSA 40 15 67 64*  40 102 78 35 127 71 35 218 72 41 252
Hgb 8.3 7.9 8.7 7.8* 7.5 8.2 7.8 7.4 8.2 8.1 7.4 8.3 7.6 6.4 7.9
LDH 196 180 217 209 188 230 194 181 259 214 172 243 194 184 208
ALP 81 68 99 85* 65 122 84 74 142 89 70 214 93 85 100
Albumin 42 39 43 41 40 45 41 39 43 43 39 44 42 40 45
bALP 29 21 41 29* 22 67 32 22 57 46 21 116 34 28 38
PINP 46.5 17.0 95.0 51.4* 21.4 174 55.1 29.6 136 73.6 28.3 146 43.5 37.6 55.8
uNTx 57.0 20.2 78.8 52.5* 35.3 119 45.8 21.9 97.3 49.9 31.3 83.3 67.0 48.0 140
YKL-40 72 38 107 82 53 143 132 63 155 78 58 140 192 145 242
8-oxo-G 28.8 25.5 39.9 31.4* 28.0 41.3 – – – – – – – – –
8-oxo-dG 17.9 15.7 24.4 17.0 15.7 23.3 – – – – – – – – –
*, P<0.05, week 12 compared with baseline. PSA, prostate-specific antigen (µg/L, ref. <4); Hgb, hemoglobin (mmol/L, ref. 8.3–10.5); LDH, 
lactate dehydrogenase (U/L, ref. 115–255); ALP, alkaline phosphatase (U/L, ref. 35–105); Albumin (g/L, ref. 34–45); PINP, pro-collagen type 
1 N-terminal (µg/L); bALP, bone-specific alkaline phosphatase (U/L, ref. 12–44); uNTx, urinary type I collagen cross-linked N telopeptides 
(nmol/µmol urine creatinine, ref. 21–83); YKL-40 (ng/mL, ref. 14–155); 8-oxo-dG, 8-oxo-7,8-dihydro-2’-deoxyguanosine (nmol); 8-oxo-G, 
8-oxo-guanosine (nmol). 
Table 4 Biomarkers for efficacy in all patients evaluated for the extension arm at week 12
Parameter
N [%]
Week 0 (n=20) Week 12 (n=20) Week 20 (n=15) Week 26 (n=14) Week 52 (n=6)
CRP
<3 14 [70] 12 [60] 6 [40] 9 [64] –
3–10 4 [20] 2 [10] 6 [40] 3 [21] –
>10 2 [10] 6 [30] 3 [20] 2 [14] –
ECOG PS
0 17 [85] 17 [85] 12 [80] 10 [71] 4 [33]
1 3 [15] 2 [10] 3 [20] 4 [29] 2 [67]
2 – 1 [5] – – –
CRP, C-reactive protein (mg/L, ref. <10); ECOG PS, Eastern Cooperative Oncology Group Performance Status.
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1–37, P=0.003). Five patients had a lower PSA at 12 weeks 
than at the baseline, and the maximum response (−27%) 
represented an absolute decrease of >2 µg/L.
No improvement in the secondary efficacy markers 
was observed. The median ALP level increased (P=0.01) 
and the Hgb level decreased (P=0.0001) from the baseline 
to 12 weeks. The LDH level tended to increase and the 
albumin level to decrease, implying disease progression. No 
marker for bone turnover decreased, but minor increases of 
14–20% were observed, as shown in Table 5. The following 
results were found for the outcomes, dichotomized as 
a decrease or increase from the baseline: 9 patients had 
no response for any bone marker, 7 patients showed a 
response for 1 biomarker, 2 patients showed a response 
for 2 biomarkers, and 2 patients showed a decrease in all 
3 biomarkers. None of the patients started antiresorptive 
therapy during the intervention period; 2 patients received 
120 mg/4 weeks denosumab prior to and during the trial, 
and 6/15 patients with follow-up data started denosumab at 
some point during the follow-up period. 
Markers of inflammation and oxidative stress did not 
change from the baseline, except for a minor increase in 
8-oxodG (DNA damage) (P=0.03). The dichotomized CRP 
response with a normal range cut-off (>10) did not differ 
from the baseline to 12 weeks by McNemar’s test. 
Three patients (19%) showed reductions in BSI and the 
number of lesions at 12 weeks compared to the baseline; all 
had one fewer high-probability lesion. Details by week are 
shown in Table 6. For technical reasons, 3 bone scans were 
missing from the analysis at baseline, and 1 bone scan was 
missing at weeks 12 and 26, leaving only 16 paired datasets 
for evaluation.
HRQoL and ECOG performance status
Sixteen patients (80%) had an unchanged ECOG score 
at week 12; 2 patients had an improved score, and 2 had 
a worse score, with a drop of 1–2 steps. Table 7 shows the 
HRQoL data. Only 1 scale, physical functioning, differed 
from baseline to week 12, and no trends of improvement 
were seen for the other scales.
Safety
A total of 53 AEs were recorded in the trial; 5/23 patients 
(21.7%) had no AEs, and 4/23 patients (17.3%) had only 
one AE. Detailed data are shown in Table 8. Eleven of 
the AEs were recorded as serious due to hospitalization, 
although three of them were elective procedures. One 
patient discontinued the AA therapy due to side effects 
(increased lower-urinary-tract symptoms). The most 
frequent findings were hypertension and anemia. Two 
episodes of pulmonary embolism were recorded, although 
one episode was asymptomatic and was discovered by a pre-
chemotherapy-evaluation CT scan during the post-trial 
follow-up. 
Discussion
The present study does not indicate that high-dose IV AA 
given once per week for 12 weeks induces tumor regression, 
as evaluated by a significant PSA reduction in patients with 
mCRPC, although the plasma concentrations of AA did 
reach the cytotoxic range for cancer cells. This result is in 
accord with all previous prospective studies, which showed no 
clinical signs of tumor growth inhibition (26). In the present 
trial, 12 (52%) of the 23 enrolled patients experienced either 
biochemical or clinical progression (leading to withdrawal) at 
6 weeks, which is a short time to progression compared to a 
Table 6 Bone scan index and number of high-probability lesions 
Study week BSI Q1 Q3 No. of lesions Q1 Q3
Week 0 (n=17) 0.23 0.05 0.64 2 1 7
Week 12 (n=19) 0.51 0.01 1.62 2 0 5
BSI, bone scan index, or median % of body skeleton infiltrated by bone metastasis, as calculated using EXINI bone software.
Table 5 Changes in biomarkers for bone metabolism between 
baseline and week 12 
Biomarker Change Q1 Q3 Change in %
uNTx +5.8 −0.2 +26.3 +14
bALP +4 0 +25 +17
PINP +4 −3.2 +47 +20
Reported as median, Q1–Q3. PINP, pro-collagen type 1 
N-terminal (µg/L); bALP, bone-specific alkaline phosphatase  
(U/L); uNTx, urinary type I collagen cross-linked N telopeptides 
(nmol/µmol urine creatinine).
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similar cohort studied previously (27).
The criteria for an 8-week treatment extension were 
based on PCWG-1 recommendations, which imply a 
survival benefit (11). The use of a ≥50% PSA response as the 
surrogacy criterion for OS has been questioned. Based on 
data from TAX327 (28) and SWOG99-16 (29), a ≥30% PSA 
reduction may improve the accuracy of the response criterion. 
Irrespective of whether the ≥50% or ≥30% response criterion 
was applied, no patient achieved a response, as the greatest 
observed reduction in PSA was 27%.
One of the major limitations of our study is the absence 
of a control group. A spontaneous 50% PSA decline in 
mCPRC is rare; it has been previously reported to occur 
in 1.3% or 3% of cases (27,30). By using PSA as a marker 
of treatment efficacy, two major criteria are fulfilled: 
the tumor must produce PSA, and the action of the 
investigated compound must induce changes that can be 
detected as changes in PSA. To be included in the present 
trial, the tumor had to be PSA-producing, but it remains 
unknown if AA is capable of changing PSA levels per se. 
Immunotherapy may improve OS without generating a 
significant PSA response. AA may enhance immune-cell 
activity (31), but no study has shown any cancer-directed 
immunotherapy using AA alone. To pursue possible 
effects of AA not related to PSA expression by tumor cells, 
additional biomarkers of the PCWG-2 and two prognostic 
nomograms were included (10,17,18). No clear trend of 
improvement was observed for any variable. 
The long-term follow-up was primarily designed to 
identify responders and any potential lasting effects. 
Because no patient continued to the extension arm, they 
were candidates for docetaxel, which generates a selection 
bias for follow-up, with the “least-progressing” patients 
being left on-study.
Our measure of general oxidative stress-induced DNA 
and RNA damage was urinary excretion of oxidized 
nucleosides. It has previously been shown that large oral 
doses of AA do not reduce intracellular oxidative stress (32), 
and the data from the present study confirm that, even 
with the high plasma concentrations of AA obtained by 
infusion, the overall oxidative stress level did not appear to 
be affected.
Sufficient data were not collected for the calculation of the 
PSA doubling time prior to enrollment. Although the use of 
PSA kinetics as a surrogate endpoint has not been validated, 
such data could potentially provide information about the 
slowing of tumor progression (33). Our patient cohort had a 
high performance status at the baseline that remained stable 
during the intervention period. Compared to reference 
material, the QoL scores were high (34). However, the 
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Figure 2 Waterfall plot of changes in PSA after 12 weeks of intravenous ascorbic acid. Values were capped at 100%; the maximum increase 
was +397%. PSA, prostate-specific antigen.
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present study did not show a trend of improvement in QoL; 
rather, the opposite was observed. Four previous studies 
have investigated HRQoL using validated questionnaires, 
and most of them reported improvements. No study 
included a parallel control group or addressed selection 
bias or the natural course of the disease (35-38). Studies 
without a control group may overestimate the effect of the 
intervention because many cancer patients turn to CAMs to 
Table 7 Health-related quality of life at baseline and at week 12
HRQoL questionaire and scale
Week 0 Week 12
P
Median Q1 Q3 Median Q1 Q3
QLQ-C30
Global health scale
Global health 83 73 100 83 67 92 0.12
Functional scales
Physical 93 80 100 83 73 93 0.006
Role 100 83 100 92 67 100 0.15
Emotional 100 92 100 100 83 100 0.09
Cognitive 100 96 100 100 83 100 0.41
Social 100 100 100 100 100 100 0.34
Symptom scales
Fatigue 11 0 22 11 0 25 0.80
Nausea/vomiting 0 0 0 0 0 0 0.17
Pain 0 0 33 0 0 21 0.67
Dyspnea 0 0 33 0 0 0 0.76
Sleep disturbance 0 0 8 0 0 8 0.78
Appetite loss 0 0 0 0 0 0 0.07
Constipation 0 0 0 0 0 0 0.71
Diarrhea 0 0 0 0 0 0 NA
Financial impact 0 0 0 0 0 0 NA
QLQ-PR25
Functional scales
Sexual activity 0 0 17 0 0 0 0.50
Sexual functioning Not reported, n=3 Not reported, n=2 NA
Symptom scales
Urinary symptoms 19 13 34 19 13 39 0.41
Bowel symptoms 0 0 17 0 0 8 0.28
Hormonal treatment-related 
symptoms
17 11 28 17 11 22 0.29
Incontinence aid (n=3) 17 8 25 17 8 25 NA
The P values were calculated using the Wilcoxon signed-rank test. QLQ-C30, quality-of-life core 30; QLQ-PR25, quality of life questionnaire-
Prostate Module 25; NA, not available.
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Table 8 Adverse events
Occurrence G1 G2 G3 G4 G5 Description
Clinical 4 1 Hypertension
2 1 1 Urinary tract infection
3 Transurethral prostate 
resection
3 Metastatic affection of 
medulla spinalis
2 1 Flu-like symptoms
2 1 Limb pain
1 1 Musculoskeletal lesion 
after minor trauma
1 1 Pulmonary embolism
2 Shortness of breath
1 1 Pneumonia
1 Diarrhea
1 Dry eyes
1 Lower urinary tract 
symptoms
1 Osteoporotic fracture
1 Pre-syncope
Laboratory/
imaging, 
asymptomatic
6 1 Anemia
3 Aminotransferase 
elevation
3 eGFR/kidney function 
decrease
1 Leukemia
1 Atrial fibrillation
1 Bilirubin elevation
1 Hydronephrosis
1 Hypercalcemia
1 Hyponatremia
All adverse events, sorted based on the grades outlined by the 
Common Terminology Criteria for Adverse Events. G1, grade 1; 
G2, grade 2; etc.
satisfy needs other than tumor treatment, including general 
health improvement, which can potentially contribute to an 
improved QoL score (39-41).
AA is highly osmotically active and may cause fluid or 
electrolyte disturbances. However, in the present study, 
treatment-induced toxicity was limited and was likely related 
to the vehicle rather than to AA itself. The natural course of 
the advancement of mCRPC explains most of the remaining 
recorded AEs. Cancer is known to increase the risk of 
thromboembolic events and may explain the two episodes of 
pulmonary embolism (42). However, as another trial reported 
pulmonary embolism in 2 of 14 patients (43), we believe that 
future studies should continue to examine this AE.
We utilized IV infusion of AA, which represents a pulsed 
delivery with a high peak concentration and rapid clearance 
within hours. In two recent phase I trials, even higher doses 
were applied, namely 1.5 g/kg and 110 g/m2, inducing 
peak plasma concentrations of 26 and 37 mM, respectively 
(37,38). Only half of the plasma concentration of AA is 
found in the tumor tissue and the surrounding extracellular 
fluids (44), and tissue hypoxia may further attenuate AA 
toxicity (45). In vivo studies in rodents have typically 
used daily intraperitoneal administration of 4 g/kg of AA, 
which generates a stable millimolar plasma concentration 
profile over time. However, despite continued exposure 
to presumably therapeutic concentrations of AA, tumor 
volume was only reduced by 22–53% in treated animals 
compared to controls (46-48).
Thus, if AA has antineoplastic properties, it appears that 
the effect of pulsed, periodic IV AA administration may be 
limited. Whether different AA delivery approaches possess 
higher therapeutic potential in humans remains to be 
investigated in future trials.
Conclusions
Infusion with 60 g of AA once per week did not induce 
disease remission in mCRPC patients; therefore, the 
findings of the present study do not support the use of 
high-dose IV AA for late-stage PC. At present, the lack 
of efficacy of this treatment suggests that it should not be 
used outside clinical trials. A large-scale controlled trial is 
needed to determine whether high-dose IV AA displays any 
therapeutic relevance.
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